Derm Dispatch: Exploring GLP-1s’ Role in Inflammation and Skin Disease

In a recent Derm Dispatch interview, host Renata Block, MMS, PA-C, spoke with Jennifer Fisher, MMSc, PA-C, a Connecticut-based dermatology physician assistant and freelance medical writer, about the evolving role of glucagon-like peptide 1 receptor agonists (GLP-1s) in dermatology. Fisher, who previously explored this topic in her Dermatology Times article, “Exploring the Role of GLP-1 Receptor Agonists in Psoriasis”, highlighted the growing interest in these therapies, driven by their widespread use for weight management and metabolic conditions.

Fisher explained that GLP-1s—best known for their role in type 2 diabetes and weight loss—are increasingly relevant in dermatology due to their impact on inflammation and metabolic health, both of which are central to chronic skin conditions. “We know obesity and metabolic syndrome are important comorbidities in dermatology,” she noted, emphasizing that these medications may indirectly influence disease trajectories for conditions like psoriasis, hidradenitis suppurativa, and acne.

She stressed, however, that while enthusiasm is mounting, the dermatology community must remain cautious. Clinical evidence directly linking GLP-1s to dermatologic outcomes remains limited, and most insights come from secondary observations or comorbidity data. “It’s important to balance patient interest with evidence-based practice,” Fisher said, underscoring that dermatology clinicians are frequently fielding questions about these therapies given their prominence in mainstream media.

Another key point Fisher raised was the importance of interdisciplinary collaboration. With many dermatology patients already prescribed GLP-1s by primary care or endocrinology providers, dermatology clinicians need to be aware of potential adverse effects—including gastrointestinal disturbances and nutritional considerations—that may overlap with dermatologic presentations.

Looking ahead, Fisher expressed optimism that future research may clarify whether GLP-1s hold therapeutic promise beyond systemic comorbidity management. “This is a space to watch,” she remarked, pointing to the increasing number of clinical trials and real-world studies investigating novel applications of these agents. Future research could include more targeted studies, larger patient populations, and insights into long-term effects.

For clinicians, the takeaway is clear: as GLP-1s continue to expand across therapeutic areas, awareness of their mechanisms, risks, and potential dermatologic implications will be critical for providing comprehensive, evidence-based care.

Click here to read more from Fisher, and here to discover other Derm Dispatch episodes featuring Block.